Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/222243
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Perioperative chemoimmunotherapy has significantly improved survival rates for non-small cell lung cancer (NSCLC). However, current tissue biomarkers remain inadequate, underscoring the need for more sensitive and accessible alternatives to monitor relapse risk. Intratumoral B-cells are increasingly recognized for their role in enhancing immunotherapy outcomes, yet the contribution of peripheral B-cells to immune surveillance remains unexplored. Peripheral B-cell immunophenotypes were analyzed from blood samples (at diagnosis, post-neoadjuvant, and at 6- and 12-months of adjuvant treatment) in 41 stage IIIA NSCLC patients treated with perioperative nivolumab plus chemotherapy, included in the NADIM clinical trial (NCT03081689). Results were correlated with 5-year survival outcomes and validated through unsupervised clustering. An increase in the percentage of total B-cells (CD19+CD20+) and na & iuml;ve B-cells (CD19+CD20+CD24+CD38+CD27-CD10-), along with a reduction in CD20 expression on total B-cells, a decrease in the proportion of memory B-cells (CD19+CD20+CD24+CD38-/lowCD27+) and transitional B-cells (CD19+CD20+CD24++CD38++CD10+), was observed during the time encompassed between the end of neoadjuvant treatment and the posterior 6 months of adjuvant treatment. Higher levels of CD20 expression on total B-cells, along with an increased percentage of memory B-cells, or activated B-cells (CD19+CD20+CD25+), at 6- and 12-months of adjuvant treatment, were associated with increased survival. Conversely, higher levels of a newly described circulating population of CD19+CD20lowCD25lowCD27low B-cells during adjuvant treatment were linked to disease progression. Perioperative nivolumab plus chemotherapy in resectable NSCLC patients induces significant changes in peripheral B-cells. The persistence of circulating memory B-cells during adjuvant treatment might play a crucial role in survival.
Matèries
Matèries (anglès)
Citació
Citació
SIERRA RODERO, Belén, MARTÍNEZ TOLEDO, Cristina, NADAL, Ernest, MOLINA ALEJANDRE, Marta, GARCÍA CAMPELO, Rosario, GIL GONZÁLEZ, Ángeles, MASSUTI, Bartomeu, GARCÍA GRANDE, Aránzazu, DÓMINE, Manuel, INSA, Amelia, CASTRO CARPEÑO, Javier de, HUIDOBRO VENCE, Gerardo, MAJEM, Margarita, MARTÍNEZ MARTÍ, Alex, MEGIAS VAZQUEZ, Diego, LOBATO ALOSNOS, Daniel ángel, COLLAZO-LORDUY, Ana, CALVO, Virginia, PROVENCIO, Mariano, CRUZ BERMÚDEZ, Alberto. Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial). _OncoImmunology_. 2025. Vol. 14, núm. 1. [consulta: 20 de gener de 2026]. ISSN: 2162-402X. [Disponible a: https://hdl.handle.net/2445/222243]